Want to see TSE:HEM full AI Analyst Report?
HEM Stock Chart & Stats
C$0.06
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.06
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.04 - C$0.14
Previous CloseN/A
Volume21.00K
Average Volume (3M)138.35K
Market Cap
C$13.85M
Enterprise ValueC$14.32M
Total Cash (Recent Filing)C$319.24K
Total Debt (Recent Filing)C$3.62M
Price to Earnings (P/E)―
Beta0.23
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding197,796,450
10 Day Avg. Volume155,944
30 Day Avg. Volume138,348
Financial Highlights & Ratios
PEG Ratio-0.66
Price to Book (P/B)-2.96
Price to Sales (P/S)0.00
P/FCF Ratio-3.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Autologous Therapy PlatformHemostemix’s focused autologous cell therapy platform is a durable strategic asset: platform approaches can create higher clinical and IP barriers to entry, concentrate R&D learning, and support multiple indications over time if clinical progress continues, strengthening long-term competitive positioning.
Debt Levels Restrained RecentlyAlthough debt exists, the absence of a recent spike suggests disciplined liability management. Stable debt trajectories reduce the chance of abrupt financing pressure, giving management time to execute clinical programs and seek planned capital raises without immediate solvency stress.
Cash Flow Mirrors Reported LossesA tight relationship between accounting losses and cash outflows improves forecastability of funding needs. For an early-stage biotech, predictable cash conversion (even negative) reduces risk of unexpected non-cash shocks and helps planning of financing rounds and R&D spend over coming quarters.
Bears Say
No Revenue And Widening LossesThe company generates no operating revenue and has increasing operating and net losses. Over the medium term this erodes funding runway and requires external capital to sustain R&D. Persistent losses limit internal financing options and increase dilution or debt reliance risk.
Negative Shareholders' Equity, Shrinking Asset BaseNegative equity and a contracting asset base are structural balance-sheet weaknesses. They constrain strategic flexibility, weaken creditor and investor confidence, and raise the probability of dilutive financings or onerous terms on future debt, impairing long-term stability.
Persistent Negative Operating And Free Cash FlowSustained negative operating and free cash flow with accelerating cash burn signals heavy reliance on external funding. This structural cash deficit heightens execution risk for clinical programs and makes the company sensitive to capital-market conditions over the next several quarters.
Hemostemix News
HEM FAQ
What was Hemostemix Inc’s price range in the past 12 months?
Hemostemix Inc lowest stock price was C$0.04 and its highest was C$0.14 in the past 12 months.
What is Hemostemix Inc’s market cap?
Hemostemix Inc’s market cap is C$13.85M.
When is Hemostemix Inc’s upcoming earnings report date?
Hemostemix Inc’s upcoming earnings report date is Aug 31, 2026 which is in 31 days.
How were Hemostemix Inc’s earnings last quarter?
Currently, no data Available
Is Hemostemix Inc overvalued?
According to Wall Street analysts Hemostemix Inc’s price is currently Overvalued.
Does Hemostemix Inc pay dividends?
Hemostemix Inc does not currently pay dividends.
What is Hemostemix Inc’s EPS estimate?
Hemostemix Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hemostemix Inc have?
Hemostemix Inc has 197,796,450 shares outstanding.
What happened to Hemostemix Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Hemostemix Inc?
Currently, no hedge funds are holding shares in TSE:HEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hemostemix Inc
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.